Objective Chronic kidney disease (CKD) is associated with a high economic burden, which is exacerbated by the high susceptibility to drug-related problems (DRPs) in this patient population. This study aimed to evaluate the cost-benefit ratio of medication reconciliation supplemented with medication review for inpatients with CKD, compared with the absence of this intervention. Design This was a cost-benefit analysis conducted along with a prospective interventional study. Setting The study was conducted at two hospitals in Jordan between February and May 2023. Participants The prospective interventional study included 142 admitted patients with CKD. Interventions Patients received medication reconciliation at admission and discharge as well as medication review throughout admission. Primary and secondary outcome measures The primary outcome measures were the net benefit and the benefit-to-cost ratio of the intervention. A cost-benefit analysis was conducted from the healthcare system perspective by assessing the cost of the service (the pharmacist time required to complete the service per patient) and the economic benefit, including total and per-patient cost savings and cost avoidance. Results The total estimated cost of all DRPs in the absence of interventions (cost avoidance) was $83 052 (average of $585±308 per patient); among which $20 623 was attributed to medication discrepancies. The cost savings were estimated at –$467. The supplemented medication reconciliation service was estimated to cost $714. As a result, the estimated net benefit totalled $81 871, averaging $577 per patient, with a benefit-to-cost ratio of 115.7:1 over the 4-month study period. Conclusions Delivering a supplemented medication reconciliation service by a clinical pharmacist for patients with CKD is cost beneficial from the healthcare perspective in Jordan, an example of a low- and middle-income country. This finding further confirms the pivotal role of clinical pharmacists in multidisciplinary healthcare teams.
Oral mucosal delivery of drugs promotes rapid absorption and high bioavailability, with a subsequent immediate onset of pharmacological effect. However, many oral mucosal deliveries are compromised by the possibility of the patient swallowing the active substance before it has been released and absorbed locally into the systemic circulation. The aim of this research was to introduce a new glimepiride formula for sublingual administration and rapid drug absorption that can be used in an emergency. The new sublingual formulation was prepared after five trials to prepare the suitable formulation. Two accepted formulations of the new sublingual product were prepared, but one of them with disintegration time of 1.45 min and searching for preferred formulation, the binder, is changed with Flulac and starch slurry to prepare formula with disintegration time of 21 seconds that supports the aim of research to be used in an emergency. The five formulations were done, after adjusting to the binder as Flulac and aerosil with disintegration time of 21 seconds and accepted hardness as well as the weight variation. The assay of a new product (subglimepiride) is 103% which is a promising result, confirming that the formula succeeded. The new product (subglimepiride) is accepted in most quality control tests and it is ready for marketing.
14 April 2025 in Journal of Pharmaceutical Policy and Practice
Chronic kidney disease (CKD) with its associated comorbidities and pill burden can expose patients to a heightened risk of drug-related problems, including medication discrepancies. This study aimed to evaluate the impact of medication reconciliation supplemented with medication review on the number of medication discrepancies at discharge and all-cause readmission among CKD patients. This was a quasi-experimental trial among adult CKD patients admitted into two major referral hospitals in northern Jordan. Patients in the intervention group received medication reconciliation supplemented with medication review by a clinical pharmacist, while those in the control group received the usual care. The recognised discrepancies were evaluated at admission and at discharge in both groups. Participants were followed for 90-day readmission. Among patients in the intervention group, the average number of discrepancies was 2.5 ± 2.2 per CKD patient. Compared to the control group, the reduction in discrepancy numbers between admission and discharge was higher in the intervention group by 1.66 discrepancies. The likelihood of 90-day readmission was significantly lower in the intervention group (OR = 0.41; P = 0.002). Supplemented medication reconciliation among CKD patients reveals a favourable impact on medication discrepancies and readmission rates. Optimising medication management during transitions of care can improve overall health outcomes.
1 January 2021 in The Thai Journal of Pharmaceutical Sciences
In light of recent developments in the scientific and technological world, herbs are widely used as remedial agents. This study was aimed to formulate and evaluate the safety and the efficacy of herbal antidandruff shampoo from Ziziphus spina-christi (Sidr) leaves extract, which is used traditionally for several medical and cosmetic purposes. Sidr leaves were extracted by maceration using ethanol as a solvent. The antifungal activity of the plant extract was tested against M. furfur. In-vivo study of the extract has been evaluated with daily oral doses (50, 100, and 200 mg/kg) for 28 days for tested rats, followed by, evaluation of the biochemical and histological parameters. Subsequently, the plant extract was formulated as a shampoo and tested for its antidandruff efficiency on 80 volunteers, with dandruff, for four consecutive weeks. An obvious antifungal activity against M. furfur has been displayed by sidr extract, where 86% of the tested volunteers substantially ameliorated from dandruff with sidr shampoo formulation. The toxicity of the extract was not shown aberrant results as compared with the control group in biochemical analysis. However, mild histological harmful effects on the liver and kidney tissues appeared at high doses of the extract, 100 and 200mg/kg, when used orally. As a conclusion, sidr extract could be used topically as anti-dandruff shampoo formulation with high efficiency and good safety.
24 December 2025 in International Journal for Quality in Health Care
Background: Patients with chronic kidney disease (CKD) often experience a poor quality of life (QoL), prolonged hospital stays (length of stay, LOS), and an increased risk of drug-related problems (DRPs) due to high comorbidity rates, pill burden, and frequent care transitions. Providing effective management can significantly improve the overall health status of CKD patients. This study evaluated the impact of the pharmacist-led medication reconciliation service on health-related QoL and LOS in CKD inpatients and the prevalence of DRPs in this population. Methods: This 9-month prospective quasi-experimental study was conducted on hospitalized patients with CKD in two phases: a control period and an intervention period. Control phase care followed usual hospital practice. In the intervention phase, the pharmacist carried out reconciliation and review of medications over the stay. Patients’ data were collected from hospital records and patient interviews. Detected drug-related problems (DRPs) were discussed with the physicians. Participants were followed for 1 month after discharge to measure QoL, using the EQ-5D-5L (European Quality of Life 5 Dimensions 5 Level Version) questionnaire. Predictors of high DRP burden were analyzed via logistic regression. Multivariable quantile regression was applied to explore factors influencing LOS and QoL at discharge and at the 1-month follow-up. Results: Of the study sample (212), 142 (67%) and 70 (33%) participants were enrolled during the intervention and control periods, respectively. A mean of 7.05 (SD = 3.41) DRPs per CKD patient was recognized. Discrepancies and inappropriate medication and dosage selection were the most prevalent DRPs. Compared with the control, utility values (QoL) were higher in the intervention group at discharge (0.17 increase; 95% confidence interval [CI] = 0.048–0.298) and at follow-up (0.24 increase; 95%CI = 0.09–0.39). The intervention group had a shorter LOS by 2.43 days than the control group (95% CI = –4.49 to –0.37; P = .021). Conclusion: The pharmacist-led supplemented medication reconciliation demonstrated positive effects on QoL and LOS among CKD patients. These results support the integration of clinical pharmacy services into interdisciplinary healthcare for CKD management.